Biomimetic Therapeutics, Inc. (BMTI) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-17.13M
Depreciation and capital lease amortization expense	952.24K
Patent license fee amortization	32.23K
Net unrealized loss on foreign currency translation	1.68K
Non-cash stock-based compensation expense	2.13M
Non-cash issuance of common stock	171.64K
Bad debt expense
Loss on disposal of equipment
Receivables	491.33K
Inventory	-528.37K
Prepaid expenses	-79.68K
Deposits
Accounts payable, accrued payroll and other accrued expenses	-2.29M
Deferred revenue	-727.06K
Net cash used in operating activities	-16.97M
Capitalized patent license fees	-251.16K
Equipment deposits
Purchases of property and equipment	-17.48K
Purchases of investments	-30.37M
Sales of investments	44.56M
Net cash provided by investing activities	13.91M
Payments on capital lease obligations	-59.27K
Payments related to shelf registration statement and financing
Issuance of common stock under compensation plans	107.16K
Net cash provided by financing activities	47.89K
Net increase (decrease) in cash and cash equivalents	-3.01M
Cash and cash equivalents, beginning of period	18.5M
Cash and cash equivalents, end of period	15.49M
Interest paid	2.83K

Entities mentioned with BMTI

View All Entities